In patients who experience disease progression after etoposide , doxorubicin , cisplatin with mitotane ( EDP-M ) , gemcitabine and metronomic capecitabine , or the less used streptozotocin , represent a second-line chemotherapy option .
Adrenocortical carcinoma: current treatment options. In this article, we focus on the current and future treatment options for adrenocortical carcinoma (ACC). ### Recent Findings Radical surgery remains the only curative treatment for ACC. Recent reports showed a longer overall survival (OS) in patients with high risk of recurrence treated with adjuvant mitotane; the time in target range (14-20 mg/l) is related to low risk of relapse both in adjuvant and in palliative setting. In patients who experience disease progression after etoposide , doxorubicin , cisplatin with mitotane ( EDP-M ) , gemcitabine and metronomic capecitabine , or the less used streptozotocin , represent a second-line chemotherapy option . temozolomide can be employed as a third-line chemotherapy. To date, unsatisfactory results have been obtained on the efficacy of targeted therapies. Clinical trials are ongoing to evaluate the efficacy of tyrosine kinase and immune checkpoint inhibitors. ### summary ACC is a rare disease with a poor prognosis. The main therapy is represented by radical surgery conducted by an expert surgeon. Adjuvant mitotane has to be started in patients with high risk of recurrence. In patients with inoperable disease, the scheme EDP-M is the most employed. Few data are available on second-line and third-line chemotherapy in patients with disease progression after EDP-M. Currently, the role of targeted therapies is under evaluation.
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            Adrenocortical carcinoma: current treatment options. In this article, we focus on the current and future treatment options for adrenocortical carcinoma (ACC). ### Recent Findings Radical surgery remains the only curative treatment for ACC. Recent reports showed a longer overall survival (OS) in patients with high risk of recurrence treated with adjuvant mitotane; the time in target range (14-20 mg/l) is related to low risk of relapse both in adjuvant and in palliative setting. In patients who experience disease progression after etoposide , doxorubicin , cisplatin with mitotane ( EDP-M ) , gemcitabine and metronomic capecitabine , or the less used streptozotocin , represent a second-line chemotherapy option . temozolomide can be employed as a third-line chemotherapy. To date, unsatisfactory results have been obtained on the efficacy of targeted therapies. Clinical trials are ongoing to evaluate the efficacy of tyrosine kinase and immune checkpoint inhibitors. ### summary ACC is a rare disease with a poor prognosis. The main therapy is represented by radical surgery conducted by an expert surgeon. Adjuvant mitotane has to be started in patients with high risk of recurrence. In patients with inoperable disease, the scheme EDP-M is the most employed. Few data are available on second-line and third-line chemotherapy in patients with disease progression after EDP-M. Currently, the role of targeted therapies is under evaluation.

            ### Response:
            etoposide, doxorubicin, cisplatin, mitotane, gemcitabine, capecitabine, streptozotocin
            